SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Delerive, P.,Fruchart, J. C., andStaels, B. ( 2001) Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169, 453459.
  • 2
    Desvergne, B. andWahli, W. ( 1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 20, 649688.
  • 3
    Glass, C. K. ( 1994) Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr. Rev. 15, 391407.
  • 4
    Kaundal, R. K. andSharma, S. S. ( 2010) Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect. 23, 241256.
  • 5
    Braissant, O.,Foufelle, F.,Scotto, C.,Dauca, M., andWahli, W. ( 1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354366.
  • 6
    Heneka, M. T. andLandreth, G. E. ( 2007) PPARs in the brain. Biochim. Biophys. Acta 1771, 10311045.
  • 7
    Heneka, M. T.,Sastre, M.,Dumitrescu-Ozimek, L.,Hanke, A.,Dewachter, I., et al. ( 2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1–42 levels in APPV717I transgenic mice. Brain 128, 14421453.
  • 8
    Kalonia, H.,Kumar, P., andKumar, A. ( 2010) Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease. Pharmacol. Biochem. Behav. 96, 115124.
  • 9
    Schintu, N.,Frau, L.,Ibba, M.,Caboni, P.,Garau, A., et al. ( 2009) PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 29, 954963.
  • 10
    Sastre, M.,Klockgether, T., andHeneka, M. T. ( 2006) Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 24, 167176.
  • 11
    Xu, H. E. andLi, Y. ( 2008) Ligand-dependent and -independent regulation of PPAR gamma and orphan nuclear receptors. Sci. Signal. 1, pe52.
  • 12
    Kliewer, S. A.,Umesono, K.,Noonan, D. J.,Heyman, R. A., andEvans, R. M. ( 1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771774.
  • 13
    Perissi, V.,Jepsen, K.,Glass, C. K., andRosenfeld, M. G. ( 2010) Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 11, 109123.
  • 14
    Puigserver, P. andSpiegelman, B. M. ( 2003) Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24, 7890.
  • 15
    Collingwood, T. N.,Urnov, F. D., andWolffe, A. P. ( 1999) Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Endocrinol. 23, 255275.
  • 16
    Nishihara, E.,O'Malley, B. W., andXu, J. ( 2004) Nuclear receptor coregulators are new players in nervous system development and function. Mol. Neurobiol. 30, 307325.
  • 17
    Puigserver, P.,Wu, Z.,Park, C. W.,Graves, R.,Wright, M., et al. ( 1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829839.
  • 18
    Katsouri, L.,Parr, C.,Bogdanovic, N.,Willem, M., andSastre, M. ( 2011) PPARgamma co-activator-1alpha (PGC-1alpha) reduces amyloid-beta generation through a PPARgamma-dependent mechanism. J. Alzheimers Dis. 25, 151162.
  • 19
    Wareski, P.,Vaarmann, A.,Choubey, V.,Safiulina, D.,Liiv, J., et al. ( 2009) PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J. Biol. Chem. 284, 2137921385.
  • 20
    Rodgers, J. T.,Lerin, C.,Gerhart-Hines, Z., andPuigserver, P. ( 2008) Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 582, 4653.
  • 21
    Esterbauer, H.,Oberkofler, H.,Krempler, F., andPatsch, W. ( 1999) Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 62, 98102.
  • 22
    Puigserver, P. ( 2005) Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int. J. Obes. (Lond.) 29, S5S9.
  • 23
    Tsunemi, T. andLa Spada, A. R. ( 2012) PGC-1alpha at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond. Prog. Neurobiol. 97, 142151.
  • 24
    St-Pierre, J.,Drori, S.,Uldry, M.,Silvaggi, J. M.,Rhee, J., et al. ( 2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397408.
  • 25
    Rodgers, J. T.,Lerin, C.,Haas, W.,Gygi, S. P.,Spiegelman, B. M., et al. ( 2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434, 113118.
  • 26
    Tritos, N. A.,Mastaitis, J. W.,Kokkotou, E. G.,Puigserver, P.,Spiegelman, B. M., et al. ( 2003) Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC 1alpha) expression in the murine brain. Brain Res. 961, 255260.
  • 27
    Rytinki, M. M. andPalvimo, J. J. ( 2009) SUMOylation attenuates the function of PGC-1alpha. J. Biol. Chem. 284, 26184261893.
  • 28
    Lagouge, M.,Argmann, C.,Gerhart-Hines, Z.,Meziane, H.,Lerin, C., et al. ( 2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 11091022.
  • 29
    Tsunemi, T.,Ashe, T. D.,Morrison, B. E.,Soriano, K. R.,Au, J., et al. ( 2012) PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci. Transl. Med. 4, 142ra97.
  • 30
    Sahin, E.,Colla, S.,Liesa, M.,Moslehi, J.,Muller, F. L., et al. ( 2011) Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359365.
  • 31
    Leone, T. C.,Lehman, J. J.,Finck, B. N.,Schaeffer, P. J.,Wende, A. R., et al. ( 2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3, e101.
  • 32
    Lin, J.,Wu, P. H.,Tarr, P. T.,Lindenberg, K. S.,St-Pierre, J., et al. ( 2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119, 121135.
  • 33
    Ma, D.,Li, S.,Lucas, E. K.,Cowell, R. M., andLin, J. D. ( 2010) Neuronal inactivation of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) protects mice from diet-induced obesity and leads to degenerative lesions. J. Biol. Chem. 285, 3908730995.
  • 34
    Chaturvedi, R. K.,Adhihetty, P.,Shukla, S.,Hennessy, T.,Calingasan, N., et al. ( 2009) Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 18, 30483065.
  • 35
    Weydt, P.,Pineda, V. V.,Torrence, A. E.,Libby, R. T.,Satterfield, T. F., et al. ( 2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4, 349362.
  • 36
    Cui, L.,Jeong, H.,Borovecki, F.,Parkhurst, C. N.,Tanese, N., et al. ( 2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 5969.
  • 37
    Xiang, Z.,Valenza, M.,Cui, L.,Leoni, V.,Jeong, H. K., et al. ( 2011) Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease. J. Neurosci. 31, 95449553.
  • 38
    Rochet, J. C.,Hay, B. A., andGuo, M. ( 2012) Molecular insights into Parkinson's disease. Prog. Mol. Biol. Transl. Sci. 107, 125188.
  • 39
    Lindholm, D.,Eriksson, O.,Mäkelä, J.,Belluardo, N., andKorhonen, L. ( 2012) PGC-1α: a master gene that is hard to master. Cell. Mol. Life Sci. 69, 24652468.
  • 40
    Ciron, C.,Lengacher, S.,Dusonchet, J.,Aebischer, P., andSchneider, B. L. ( 2012) Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum. Mol. Genet. 21, 18611876.
  • 41
    Mudo, G.,Makela, J.,Di Liberto, V.,Tselykh, T. V.,Olivieri, M., et al. ( 2012) Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell. Mol. Life Sci. 69, 11531165.
  • 42
    Seibler, P.,Graziotto, J.,Jeong, H.,Simunovic, F.,Klein, C., et al. ( 2011) Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J. Neurosci. 31, 59705976.
  • 43
    Shin, J. H.,Ko, H. S.,Kang, H.,Lee, Y.,Lee, Y. I., et al. ( 2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144, 689702.
  • 44
    Ebrahim, A. S.,Ko, L. W., andYen, S. H. ( 2010) Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein. Neurosci. Lett. 473, 120125.
  • 45
    Zheng, B.,Liao, Z.,Locascio, J. J.,Lesniak, K. A.,Roderick, S. S., et al. ( 2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2, 52ra73.
  • 46
    Qin, W.,Haroutunian, V.,Katsel, P.,Cardozo, C. P.,Ho, L., et al. ( 2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch. Neurol. 66, 352361.
  • 47
    Gong, B.,Chen, F.,Pan, Y.,Arrieta-Cruz, I.,Yoshida, Y., et al. ( 2010) SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging Cell 9, 10181031.
  • 48
    Kim, D.,Nguyen, M. D.,Dobbin, M. M.,Fischer, A.,Sananbenesi, F., et al. ( 2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 31693179.
  • 49
    Marambaud, P.,Zhao, H., andDavies, P. ( 2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 280, 3737737382.
  • 50
    Beher, D.,Wu, J.,Cumine, S.,Kim, K. W.,Lu, S. C., et al. ( 2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74, 619624.
  • 51
    Redler, R. L. andDokholyan, N. V. ( 2012) The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog. Mol. Biol. Transl. Sci. 107, 215262.
  • 52
    Da Cruz, S.,Parone, P. A.,Lopes, V. S.,Lillo, C.,McAlonis-Downes, M., et al. ( 2012) Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab. 15, 778786.
  • 53
    Liang, H.,Ward, W. F.,Jang, Y. C.,Bhattacharya, A.,Bokov, A. F., et al. ( 2011) PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve 44, 947956.
  • 54
    Zhao, W.,Varghese, M.,Yemul, S.,Pan, Y.,Cheng, A., et al. ( 2011) Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1alpha) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol. Neurodegener. 6, 51.
  • 55
    Augereau, P.,Badia, E.,Carascossa, S.,Castet, A.,Fritsch, S., et al. ( 2006) The nuclear receptor transcriptional coregulator RIP140. Nucl. Recept. Signal. 4, e024.
  • 56
    Christian, M.,White, R., andParker, M. G. ( 2006) Metabolic regulation by the nuclear receptor corepressor RIP140. Trends Endocrinol. Metab. 17, 243250.
  • 57
    Seth, A.,Steel, J. H.,Nichol, D.,Pocock, V.,Kumaran, M. K., et al. ( 2007) The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metab. 6, 236245.
  • 58
    Zschiedrich, I.,Hardeland, U.,Krones-Herzig, A.,Berriel Diaz, M.,Vegiopoulos, A., et al. ( 2008) Coactivator function of RIP140 for NFkappaB/RelA-dependent cytokine gene expression. Blood 112, 264276.
  • 59
    Nautiyal, J.,Steel, J. H.,Rosell, M. M.,Nikolopoulou, E.,Lee, K., et al. ( 2010) The nuclear receptor cofactor receptor-interacting protein 140 is a positive regulator of amphiregulin expression and cumulus cell-oocyte complex expansion in the mouse ovary. Endocrinology 151, 29232932.
  • 60
    Castet, A.,Boulahtouf, A.,Versini, G.,Bonnet, S.,Augereau, P. et al. ( 2004) Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibition. Nucleic Acids Res. 32, 19571966.
  • 61
    Vo, N.,Fjeld, C., andGoodman, R. H. ( 2001) Acetylation of nuclear hormone receptor-interacting protein RIP140 regulates binding of the transcriptional corepressor CtBP. Mol. Cell. Biol. 21, 61816188.
  • 62
    Wei, L. N.,Hu, X.,Chandra, D.,Seto, E., andFarooqui, M. ( 2000) Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing. J. Biol. Chem. 275, 4078240787.
  • 63
    Hallberg, M.,Morganstein, D. L.,Kiskinis, E.,Shah, K.,Kralli, A. et al. ( 2008) A functional interaction between RIP140 and PGC-1alpha regulates the expression of the lipid droplet protein CIDEA. Mol. Cell. Biol. 28, 67856795.
  • 64
    Duclot, F.,Lapierre, M.,Fritsch, S.,White, R.,Parker, M. G., et al. ( 2012) Cognitive impairments in adult mice with constitutive inactivation of RIP140 gene expression. Genes Brain Behav. 11, 6978.
  • 65
    Ghosh, S. andThakur, M. K. ( 2008) Tissue-specific expression of receptor-interacting protein in aging mouse. Age (Dordr). 30, 237243.
  • 66
    Zhang, X. R.,Zeng, C. M.,Du, J. B.,Liang, R.,Yang, L. J. et al. ( 2007) [Expression profile of receptor-interacting protein 140 in the brain: experiment with prenatal and postnatal mice]. Zhonghua Yi Xue Za Zhi. 87, 31523154.
  • 67
    Gardiner, K. ( 2006) Transcriptional dysregulation in Down syndrome: predictions for altered protein complex stoichiometries and post-translational modifications, and consequences for learning/behavior genes ELK, CREB, and the estrogen and glucocorticoid receptors. Behav. Genet. 36, 439453.
  • 68
    Saltiel, A. R. ( 2011) Derepressing nuclear receptors for metabolic adaptation. Cell 147, 717178.
  • 69
    Li, P.,Fan, W.,Xu, J.,Lu, M.,Yamamoto, H., et al. ( 2011) Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity. Cell 147, 815826.
  • 70
    Yamamoto, H.,Williams, E. G.,Mouchiroud, L.,Canto, C.,Fan, W., et al. ( 2011) NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell 147, 827839.
  • 71
    van der Laan, S.,Lachize, S. B.,Schouten, T. G.,Vreugdenhil, E.,de Kloet, E. R., et al. ( 2005) Neuroanatomical distribution and colocalisation of nuclear receptor corepressor (N-CoR) and silencing mediator of retinoid and thyroid receptors (SMRT) in rat brain. Brain Res. 1059, 113121.
  • 72
    Hermanson, O.,Jepsen, K., andRosenfeld, M. G. ( 2002) N-CoR controls differentiation of neural stem cells into astrocytes. Nature 419, 934939.
  • 73
    Lubensky, I. A.,Vortmeyer, A. O.,Kim, S.,Lonser, R. R.,Park, D. M., et al. ( 2006) Identification of tumor precursor cells in the brains of primates with radiation-induced de novo glioblastoma multiforme. Cell Cycle 5, 452456.